These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34075640)

  • 1. The role of stroke nurses in thrombolysis administration in Australia and the United Kingdom: A cross-sectional survey of current practice.
    Hamilton H; Dale S; McElduff B; Craig LE; Fasugba O; McInnes E; Alexandrov AW; Cadilhac DA; Lightbody E; Watkins DC; Middleton S
    J Clin Nurs; 2022 Jan; 31(1-2):158-166. PubMed ID: 34075640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
    ; Sandercock P; Wardlaw JM; Lindley RI; Dennis M; Cohen G; Murray G; Innes K; Venables G; Czlonkowska A; Kobayashi A; Ricci S; Murray V; Berge E; Slot KB; Hankey GJ; Correia M; Peeters A; Matz K; Lyrer P; Gubitz G; Phillips SJ; Arauz A
    Lancet; 2012 Jun; 379(9834):2352-63. PubMed ID: 22632908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the implementation of a 24-hr stroke thrombolysis emergency treatment for patients with acute ischaemic stroke.
    Zhao J; Li X; Liang Y; Zhao L; Zhang X; Liu Y
    J Clin Nurs; 2018 May; 27(9-10):2161-2167. PubMed ID: 29345016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis for acute ischaemic stroke.
    Wardlaw JM; Zoppo G; Yamaguchi T; Berge E
    Cochrane Database Syst Rev; 2003; (3):CD000213. PubMed ID: 12917889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
    Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.
    Zinkstok SM; Vermeulen M; Stam J; de Haan RJ; Roos YB;
    Trials; 2010 May; 11():51. PubMed ID: 20459856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register.
    Lees KR; Ford GA; Muir KW; Ahmed N; Dyker AG; Atula S; Kalra L; Warburton EA; Baron JC; Jenkinson DF; Wahlgren NG; Walters MR;
    QJM; 2008 Nov; 101(11):863-9. PubMed ID: 18694900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular basis of thrombolysis and its clinical application in stroke.
    Murray V; Norrving B; Sandercock PA; Terént A; Wardlaw JM; Wester P
    J Intern Med; 2010 Feb; 267(2):191-208. PubMed ID: 20175866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
    Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
    Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
    Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
    Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke.
    Daou B; Deprince M; D'Ambrosio R; Tjoumakaris S; Rosenwasser RH; Ackerman DJ; Bell R; Tzeng DL; Ghobrial M; Fernandez A; Shah Q; Gzesh DJ; Murphy D; Castaldo JE; Mathiesen C; Pineda MC; Jabbour P
    Clin Neurol Neurosurg; 2015 Dec; 139():264-8. PubMed ID: 26539671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: a survey of barriers and enablers.
    Williams JM; Jude MR; Levi CR
    Aust J Rural Health; 2013 Oct; 21(5):262-7. PubMed ID: 24118148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous thrombolysis in the emergency department for the treatment of acute ischaemic stroke.
    Semplicini A; Benetton V; Macchini L; Realdi A; Manara R; Carollo C; Parotto E; Mascagna V; Leoni M; Calò LA; Pessina AC; Tosato F
    Emerg Med J; 2008 Jul; 25(7):403-6. PubMed ID: 18573948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Outcomes of Patients who Refuse Intravenous Thrombolysis for Acute Ischemic Stroke - The San Diego Experience.
    von Kleist T; Meyer D; Rapp K; Meyer BC; Modir R
    J Stroke Cerebrovasc Dis; 2020 Nov; 29(11):105137. PubMed ID: 33066942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment.
    Vandelli L; Marietta M; Trenti T; Varani M; Bigliardi G; Rosafio F; Dell'acqua ML; Picchetto L; Nichelli P; Zini A
    Adv Clin Exp Med; 2019 Feb; 28(2):219-222. PubMed ID: 30507073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke thrombolysis in England: an age stratified analysis of practice and outcome.
    Bray BD; Campbell J; Hoffman A; Tyrrell PJ; Wolfe CD; Rudd AG
    Age Ageing; 2013 Mar; 42(2):240-5. PubMed ID: 23174425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.